BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
Praxis Precision Medicines (NASDAQ:PRAX – Free Report) had its price objective trimmed by Truist Financial from $175.00 to $85.00 in a research note released on Monday morning,Benzinga reports.
Looking at options history for Praxis Precision Medicine (NASDAQ:PRAX) we detected 39 trades. If we consider the specifics of each trade, it is accurate to state that 23% of the investors opened ...
Throughout the last three months, 4 analysts have evaluated Praxis Precision Medicine PRAX, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a summary of ...
Praxis Precision Medicines (NASDAQ:PRAX – Free Report) had its price objective trimmed by Robert W. Baird from $117.00 to $73.00 in a research report report published on Monday morning ...
Below is a chart showing IONQ's trailing twelve month trading history, with the $45 strike highlighted in orange: Praxis Precision Medicines Inc (Symbol: PRAX) saw options trading volume of 2,053 ...
BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback